1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Getinge AB (publ)

Getinge AB (publ)

GNGBF
Getinge AB (publ)US flagOther OTC
20.05
USD
- -
- -
5.10BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
100.04
105.5
119.61
91.7
89.72
88.75
97.51
109.48
99.31
103.87
116.85
127.62
128.38
130.33
Basic EPS, GAAP
9.04
5.67
5.5
4.91
5.49
-3.55
4.49
11.89
10.9
9.15
8.86
6.01
8.29
5.47
Free Cash Flow per Basic Share
7.36
10.2
6.76
9.29
4.39
9.19
9.59
22.59
20.67
8.19
5.89
12
9.67
9.93
Dividend per Share
3.91
3.93
2.73
2.83
1.97
1.56
1.09
1.59
3.15
4.08
4.34
4.5
4.65
4.68
Book Value per Share
49.7
49.59
52.38
56.22
49.57
41.04
43.11
53.45
61.37
69.51
73.42
75.13
79.45
73.76
Tangible Book Value per Share
-33.89
-44.98
-43.32
-45.86
-12.92
-16.31
-12.15
-2.2
3.77
12.64
-0.98
-22.14
-14.76
-20.82
Basic Weighted Avg Shares
253
253
253
242
251
272
272
272
272
272
272
272
272
272
Sales/Revenue/Turnover
25,287
26,669
30,235
22,170
22,495
24,172
26,559
29,819
27,049
28,291
31,827
34,759
34,968
35,499
Operating Margin (%)
16.46
14.42
11.31
12.08
10.03
-1.17
10.19
16.87
16.07
13.7
11.61
10.63
12.77
10.8
Depreciation Expense
- -
- -
- -
2,703
2,609
1,808
2,223
2,467
1,814
2,027
2,093
2,422
2,250
2,538
Net Income, GAAP
2,285
1,433
1,390
1,188
1,376
-967
1,222
3,239
2,970
2,491
2,412
1,638
2,258
1,490
Effective Tax Rate (%)
27.21
27.13
27.04
26.15
- -
- -
34.21
27.05
28.34
27.53
27.37
27.52
27.63
27.96
Profit Margin (%)
9.04
5.37
4.6
5.36
6.12
-4
4.6
10.86
10.98
8.8
7.58
4.71
6.46
4.2
Working Capital
4,029
1,630
3,880
3,896
2,292
4,143
4,630
7,643
4,459
7,113
3,462
3,115
4,185
2,880
LT Debt
13,566
14,378
16,006
15,914
4,962
7,378
7,068
7,687
3,495
5,031
4,960
8,280
8,922
8,975
Total Equity
16,560
18,694
19,593
20,916
19,806
19,655
20,973
21,486
25,176
30,453
30,403
33,210
29,493
29,018
Return on Invested Capital (%)
9.11
7.68
6.24
4.76
- -
- -
5.79
11.68
10.12
8.48
7.14
6.47
7.6
6.86
Return on Capital (%)
9.19
5.97
5.39
4.35
- -
- -
6.54
14.28
13.06
11.22
10.23
6.9
8.5
4.89
Return on Common Equity (%)
19.09
11.42
10.79
8.85
10.58
-8.19
10.66
24.63
18.99
13.98
12.39
8.1
10.73
7.47

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,447
2,219
2,194
LT Borrowings
6,971
8,118
7,910
LT Finance Leases
1,309
1,145
1,065
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
272
272
272
Market Capitalization
47,271
57,961
48,726

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
18,162
18,164
15,733
Cash, Cash Equivalents & STI
2,961
4,203
1,945
Accounts Receivable, Net
6,348
5,265
4,785
Inventories
6,590
6,650
6,793
Total Current Liabilities
15,047
13,888
12,853
Payables & Accruals
- -
- -
- -
ST Debt
2,447
2,219
2,194
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.59%
7.2%
-11.19%
Free Cash Flow
23.52%
-2.52%
-19.37%
Net Income, GAAP
-25.21%
-4.37%
37.85%
Sales/Revenue/Turnover
2.2%
3.52%
0.6%
Total Cash Common Dividend
11.37%
28.22%
3.26%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,513
8,305
7,870
11,071
34,759
2025
8,320
8,238
10,186
- -
34,968
2026
7,443
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.69
1.88
0.01
2.44
6.01
2025
1.1
1.92
3.19
- -
8.29
2026
1.47
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
4.44
0.02
0.04
4.5
2025
- -
4.62
0.01
- -
4.65
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Mattias Perjos
Full Time Employees
11,827
Sector
Healthcare
Industry
Medical - Devices
Address
Lindholmspiren 7A Gothenburg Sweden 417 56
IPO Date
Apr 6, 2011
Website
getinge.com
Similar Companies
EMVision Medical Devices Ltd (EMV.AX)
Beijing Chunlizhengda Medical Instruments Co., Ltd. (688236.SS)
EBR Systems, Inc. (EBR.AX)
AVDR US LargeCap Leading ETF (AVDR)
Qualis Innovations, Inc. (QLIS)
ResMed Inc. (RSMDF)
Business
Getinge AB (publ) is a global medical technology company that develops and markets innovative solutions for healthcare and life sciences, including equipment, systems, and services for acute care therapies, surgical workflows, and life science applications; its core offerings encompass products for intensive care such as mechanical ventilators and intra-aortic balloon pumps including Cardiosave and Advanta balloonable covered stents; cardiovascular procedures featuring extracorporeal membrane oxygenation and endoscopic vessel harvesting systems; operating rooms with integrated solutions, tables, lights, and OR integration technologies; sterile reprocessing including cleaning, disinfection, and sterilization equipment like sterilizers and consumables; digital health platforms; pharmaceutical production and bioprocess optimization tools such as Aquadis and DPTE-EXO; as well as research laboratory equipment and organ preservation devices from its Paragonix Technologies portfolio targeting heart, lung, and abdominal transplant segments. Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge operates manufacturing facilities in the United States, France, the Netherlands, China, Germany, Poland, Sweden, Turkey, and the UK, with products sold in over 135 countries and a workforce exceeding 10,000 employees serving hospitals, ambulatory surgery centers, and life science customers worldwide. In recent developments, Getinge completed the acquisition of Paragonix Technologies in September 2024 for approximately USD 253 million upfront plus potential earn-outs up to USD 224 million, enhancing its organ transport portfolio amid a rapidly growing transplant market projected to exceed USD 10 billion by 2034; the company regained the CE Mark for its Cardiosave intra-aortic balloon pump with deliveries resuming in late 2025, while Advanta stents received approvals for three additional indications to bolster European market presence; additionally, Getinge reported high organic sales growth and stronger margins in its July-September 2025 interim report, with Paragonix fully integrated and expansion accelerating beyond the US, alongside ongoing quality improvements and a record 2024 performance.

Company News

APIChat

  • seekingalpha.com

    Getinge AB (publ) (GNGBF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (publ) (GNGBF) Q1 2025 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (GNGBF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (GNGBF) Q3 2024 Earnings Call Transcript

  • seekingalpha.com

    Getinge AB (GNGBF) Q2 2024 Earnings Call Transcript